Skip to main content
AHN-GOOK PHARMACEUTICAL Co., Ltd. logo

AHN-GOOK PHARMACEUTICAL Co., Ltd. — Investor Relations & Filings

Ticker · 001540 ISIN · KR7001540004 KO Manufacturing
Open in API
Filings indexed 170 across all filing types
Latest filing 2026-04-17 Major Shareholding Noti…
Country KR South Korea
Listing KO 001540

About AHN-GOOK PHARMACEUTICAL Co., Ltd.

https://www.no1health2.or.kr:19621/

AHN-GOOK PHARMACEUTICAL Co., Ltd. is a pharmaceutical company that develops, manufactures, and markets a broad range of medicines. The company has a strong focus on treatments for the respiratory system and cardiovascular diseases. Its product portfolio includes prescription drugs, over-the-counter medications, and health supplements, with notable products such as Synatura Syrup for respiratory conditions, as well as treatments for digestive and ophthalmic health. The company is dedicated to promoting human health and improving quality of life through the development of innovative and effective pharmaceutical solutions for a global market.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a Korean ‘주식등의 대량보유상황보고서(일반)’ – a large shareholding status report filed under the Capital Markets Act (capital market regulations). It details a change in major shareholdings of the issuer, including thresholds, ownership percentages, and related contracting. This corresponds exactly to a Major Shareholding Notification (MRQ).
2026-04-17 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 1% confidence The document is a Korean autonomous disclosure (“자율공시”) titled “기업가치 제고 계획,” a corporate value enhancement plan required under tax law. It outlines future product differentiation strategy and shareholder return policy including dividend targets, rather than reporting actual financial results or providing a report itself. It is not an earnings release, dividend notice alone, investor presentation, or standard financial report, but a regulatory announcement of strategic plans. It therefore falls into the general Regulatory Filings fallback category.
2026-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal report detailing the results of an annual general shareholders’ meeting, including vote outcomes on financial statement approval, dividend resolutions, board and auditor elections, and amendments to the articles of incorporation. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-03-26 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for the 68th fiscal year (2025) of Ahn-Gook Pharmaceutical Co., Ltd. It contains comprehensive company information, financial data, management discussion, and governance details, which is the standard format for an Annual Report (10-K equivalent in the Korean regulatory context). FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It contains the auditor's opinion, financial statements (consolidated and separate), and key financial metrics for the fiscal year. While it provides audit-related information, it is a standard regulatory disclosure of the audit results rather than a standalone audit report document or a full annual report. Therefore, it fits the 'Regulatory Filings' category as a formal disclosure of audit submission. FY 2025
2026-03-18 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Ahn-Gook Pharmaceutical Co., Ltd. It contains the agenda for the upcoming AGM, including financial statement approval, director/auditor appointments, and remuneration limits. It also includes detailed financial statements (balance sheet, income statement, etc.) as part of the 'Management Reference Materials' (경영참고사항) required for shareholder review prior to the meeting. This is a standard proxy solicitation document sent to shareholders to inform them of the meeting and request their votes, which falls under the Proxy Solicitation & Information Statement category.
2026-02-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.